%A Fang Weisheng, Lai Peibao, Wang Xiaoyan, et al %T Clinical value of adjuvant therapy for esophageal cancer after radical resection %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.011 %P 34-37 %V 41 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9274.shtml} %8 2014-01-08 %X Surgery is the standard therapy for esophageal cancer, however, the postoperative overall survival rate is still disappointed. Local recurrence and regional lymph node metastasis are the main failure models. The optimal therapeutic modality for these patients with radical resection remains unclear. Some researches indicate that patients with stage Ⅲ, N1 can benefit from postoperative radiotherapy, which can improve the diseasefree survival and overall survival ratio. The irradiation field depends on the site of tumor removal (tumor bed) during surgery. The cisplatin plus 5fluorouracil chemotherapy regimen seems as the preferred for postoperative adjuvant chemotherapy, the mainly adverse reactions are digestive tract reactions and myelosuppression. The clinical value of postoperative adjuvant chemoradiotherapy still needs more clinical trials to support.